Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT$_1$ receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis

Masaru Iwai and Masatsugu Horiuchi

Recent studies have established a new regulatory axis in the renin–angiotensin system (RAS). In this axis, angiotensin (Ang)-(1–7) is finally produced from Ang I or Ang II by the catalytic activity of angiotensin-converting enzyme 2 (ACE2). Ang-(1–7) shows actions different from those of AT$_1$ receptor stimulation, such as vasodilatation, natriuresis, anti-proliferation and an increase in the bradykinin–NO (nitric oxide) system. As the catalytic efficiency of ACE2 is approximately 400-fold higher with Ang II as a substrate than with Ang I, this axis is possibly acting as a counter-regulatory system against the ACE/Ang II/AT$_1$ receptor axis. The signaling pathway of the ACE2-Ang-(1–7) axis has not yet been totally and clearly understood. However, a recent report suggests that the Mas oncogene acts as a receptor for Ang-(1–7). Intracellular signaling through Mas is not clear yet. Several factors such as Akt phosphorylation, protein kinase C activation and mitogen-activated protein (MAP) kinase inhibition seem to be involved in this signaling pathway. Further investigations are needed to clarify the regulation and mechanism of action of ACE2 and Ang-(1–7). However, this second axis through ACE2 and Ang-(1–7) in RAS can be an important target for the therapy of cardiovascular and metabolic disorders.

Hypertension Research (2009) 32, 533–536; doi:10.1038/hr.2009.74; published online 22 May 2009

Keywords: angiotensin; angiotensin-(1–7); angiotensin-converting enzyme; Mas oncogene; receptors

INTRODUCTION
The renin–angiotensin system (RAS) has a critical role in the cardiovascular system. Recent studies on RAS have found various components and have proposed new axes of signaling pathways. In a classical system, angiotensin (Ang) II produced from Ang I by an angiotensin-converting enzyme (ACE) is a strong bioactive substance. Ang II binds to two major types of receptors, namely, Ang II type 1 (AT$_1$) and Ang II type 2 (AT$_2$) receptors, the signaling pathways of which have been well studied, including in the identification of new signaling-related molecules, such as AT$_1$ receptor-associated protein (ATRAP) and AT$_2$ receptor-interacting protein (ATIP). In cardiovascular diseases, AT$_2$-receptor stimulation seems to antagonize the signaling associated with AT$_1$-receptor stimulation. As the binding affinity of Ang II for the AT$_2$ receptor does not differ from that for the AT$_1$ receptor, it is considered that AT$_2$-receptor stimulation contributes to the beneficial actions of AT$_1$-receptor blockers (ARBs). In this context, AT$_2$-receptor agonists, such as compound 21, have been newly developed and are expected to function as useful agents against pathological disorders in the future.

Recently, a new axis of RAS has been established. In this axis, Ang I is finally converted to Ang-(1–7) by the catalytic activity of ACE2. The mechanisms of action of Ang-(1–7) are still being investigated by many research groups. Santos et al. reported that the Mas oncogene is a receptor for Ang-(1–7). There are an increasing number of reports on the role of ACE2, Ang-(1–7) and Mas in the cardiovascular system. In this review, an outline of the role and function of ACE2 with the Ang-(1–7) pathway is discussed in comparison with the classical ACE–Ang II–AT$_1$ receptor axis.

ACE, ANG II AND ANGIOTENSIN-II RECEPTORS—CLASSICAL RAS AXIS
Ang II is a well-known bioactive substance involved in the regulation of blood pressure. Ang II is involved in the exaggeration of cardiovascular disease. Recent studies indicate that Ang II is also involved in the onset of diabetes and metabolic disorders. In classical RAS, Ang II is produced from Ang I by the action of ACE. This classical axis can be called as the ACE–AngII–AT$_1$ receptor axis. Such findings are closely related to the development of RAS inhibitors, such as the ACE inhibitor and ARB. The major receptor subtypes for Ang II are the AT$_1$ and AT$_2$ receptors. The AT$_1$ receptor was cloned in 1991, and this finding has contributed to the development of ARBs and accelerated basic and clinical researches. The distribution of the AT$_1$ receptor covers most organs, whereas AT$_2$-receptor expression is observed in only a few organs after birth and is upregulated in pathological states.
AT1-receptor stimulation mediates the classical major actions of Ang II, and large clinical trials and basic researches have established the concept of the cardiovascular continuum proposed by Dzau et al.\textsuperscript{10,11} AT1-receptor stimulation is in fact known to exert hypertension, stroke, cardiovascular events and renal diseases (Figure 1). It has also been reported that the blockade of AT1 receptor promotes longevity.\textsuperscript{12}

In recent years, efforts have been carried out to produce the inhibitor of RAS. The first trial to produce a renin inhibitor did not succeed for clinical use because of chemical and technical difficulties. However, these efforts produced the ACE inhibitor. This success triggered the development of new RAS inhibitors. ACE inhibitors have some adverse effects, such as coughing. In addition, chronic administration of an ACE inhibitor showed an escape phenomenon, in which the inhibitory action of the ACE inhibitor is strongly attenuated. To solve such problems, ARB has been developed as the second RAS inhibitor. As most actions of Ang II are mediated through the AT1 receptor, the non-peptide ARB is available and widely used in the treatment of hypertension, and in cardiovascular and renal diseases.

Ang II acts mainly through AT1 receptors, using various signaling mechanisms. For example, AT1-receptor stimulation increases the influx of extracellular Ca\textsuperscript{2+} and mobilization of intracellular Ca\textsuperscript{2+}. An increase in the intracellular Ca\textsuperscript{2+} level activates acute responses, such as vascular smooth-muscle contraction, and also activates various kinases, including the mitogen-activated protein (MAP) kinase pathway, to induce cell-proliferation signaling. AT1-receptor stimulation seems to activate the EGF receptor in the plasma membrane. Therefore, a part of the action caused by AT1-receptor stimulation is similar to that caused by Ca\textsuperscript{2+}-mobilizing hormones and by the EGF family. In contrast, signaling mediated by AT2-receptor stimulation is transferred mainly by phosphatases.\textsuperscript{1} Therefore, the action of AT2-receptor stimulation is considered to be antagonized against AT1-receptor-mediated signaling. In fact, an antagonizing action or the counter-regulation of AT2-receptor stimulation has been reported previously.\textsuperscript{13–15}

**ROLES OF ACE2, ANG-(1–7) AND THE MAS AXIS—A NEW RAS PATHWAY**

Possible effects such as vasodilation mediated by Ang-(1–7) have been reported; however, the mechanisms leading to Ang-(1–7) production and its receptor were unclear, resulting in the delay of Ang-(1–7)-based researches. Recent reports show that Ang-(1–7) is produced by ACE2 activity.\textsuperscript{16,17} ACE2 is reported to be highly expressed in the heart, kidney and testis. ACE2 is a membrane-associated hydrolase and it hydrolyzes Ang I to Ang-(1–9) and Ang II to Ang-(1–7) (Figure 2).\textsuperscript{18} As Ang-(1–9) can be converted to Ang-(1–7) by ACE or by other peptides, ACE2 facilitates Ang-(1–7) production by two separate pathways.\textsuperscript{19} Ang-(1–7) loses only one amino acid from Ang II. It might be possible that Ang-(1–7) is a degradation product of Ang II and one of the inactivation mechanisms of Ang II. However, recent studies indicate that Ang-(1–7) has more active roles in RAS. Ang-(1–7) causes vasodilatation, which antagonizes AT1-receptor stimulation-mediated vasoconstriction. This effect seemed to be mediated by the bradykinin–NO (nitric oxide) pathway.\textsuperscript{18,20} Accordingly, these results suggest that Ang-(1–7) antagonized the pressor effect of AT1-receptor stimulation, suggesting that it may act as a kind of AT1-receptor antagonist, thereby resulting in a blood-pressure-lowering effect and an organ-protective effect, such as a reduction of cardiac hypertrophy and fibrosis and renal damage (Figure 3). It is reported that a lack of ACE2 accelerates the pressure-overload-induced cardiac dysfunction.\textsuperscript{21} On the other hand, the Ang-(1–7) agonist, Ang-(1–7) III, antagonizes AT1-receptor stimulation mediated hypertension.\textsuperscript{22} Consequently, the Ang-(1–7) system can act as both a physiological vasodilator and an antihypertensive agent.

**Figure 1** The role of AT1 receptor stimulation in hypertension and organ damage. NO, nitric oxide; CKD, chronic kidney disease.

**Figure 2** The production of angiotensin-(1–7) by the angiotensin-converting enzyme 2 (ACE2).
AVE0991, was cardioprotective in diabetic rats. In addition, Ang-(1–7) potentiates bradykinin, either through an AT2-receptor-dependent mechanism or through the inhibition of ACE. Recent studies have also shown that Ang-(1–7), similar to ACE inhibitors, potentiates the effect of bradykinin by inhibiting the desensitization of its receptor. It has been discovered that the catalytic efficiency of ACE2 is approximately 400-fold higher with Ang II as a substrate than with Ang I, suggesting that this second arm of the system acts as a counter-regulator of the first arm. Previous reports suggest that olmesartan, an ARB, increased the plasma concentration of Ang-(1–7) and the cardiac ACE2-expression level. Another ARB, losartan, also induced similar changes; however, its dose was 100-fold higher than that of olmesartan, suggesting that this effect of ARB is not a class effect. A more detailed analysis could show the regulation of ACE2 and Mas, which could contribute toward a new drug discovery for regulating RAS.

Recent studies on the function of ACE2 suggest that ACE2 has an important role in the severity of lung failure, such as in acute respiratory distress syndrome (ARDS) or in acute lung injury. Moreover, it has been shown that the severe acute respiratory syndrome (SARS) corona virus utilizes ACE2 as an essential receptor for cell fusion and for in vivo infections, suggesting that ACE2 contributes to SARS pathogenesis. These results indicate that ACE2 activity has an important role not only in cardiovascular diseases but also in damages or dysfunctions of other organs. We can expect the further studies on ACE2 functions to contribute toward a new therapy for organ damages that target this enzyme.

A recent report suggests that the Mas oncogene acts as a receptor for Ang-(1–7). Mas is a class of G-protein-coupled receptor containing 325 amino-acid residues. The expression of Mas is abundantly expressed in the brain and testis. Low levels of Mas expression were also observed in other tissues, such as in the heart, kidney, lung, liver, spleen, tongue and in the skeletal muscle.

**Figure 3** Action of AT1 and AT2 receptors and Mas-mediated signaling. AT1, angiotensin-II type-1 receptor; AT2, angiotensin-II type-2 receptor; NO, nitric oxide.

**Figure 4** The balance between ACE and ACE2 activities affects cardiovascular disorders. ACE, angiotensin-converting enzyme; Ang, angiotensin; AT1, angiotensin-II type-1 receptor; AT2, angiotensin-II type-2 receptor.
Mas-deficient mice showed an impairment of cardiac functions in these mice.36,37 Recent studies suggest that Rac 1, c-Jun NH2-terminal kinase (JNK), p38 MAP kinase and the activation of phosphorylase C might be involved in Mas-mediated signaling. One of the major pathways of Mas signaling in the cardiovascular system is the phosphorylation of Akt. Moreover, in cardiomyocytes, an inhibition of MAP kinase activation by Ang-(1–7) can be blocked by antiserum to oligonucleotides against Mas.38 More detailed research works can show the Mas functions more clearly.

PERTSPECTIVES OF THE ACE2-ANG-(1–7)–MAS AXIS IN CLINICAL FIELD

In recent years, several classes of RAS inhibitors have been developed and these inhibitors are effective in hypertensive patients and in hypertension-associated pathological disorders. ACE inhibitors, ARBs and renin inhibitors are already available for hypertensive patients. Moreover, the AT1-receptor agonists, such as compound 21, could be useful in the future. In previous studies, the detailed mechanism of the regulation of the ACE2–Ang–(1–7)–Mas axis was not clearly stated. However, it has been clarified that this pathway acts as a counter-regulation system against the ACE–Ang II–AT1 receptor pathway. Therefore, it is suggested that the ACE2–Ang–(1–7)–Mas axis could become a new target for the therapy of circulatory disorders and adult diseases, including that of the metabolic syndrome. The total effects of RAS seem to stand on the balance between ACE and ACE2 activities (Figure 4). In this respect, it could be considered that the classical ACE–Ang II–AT1 receptor axis plays as a ‘devil’ and the ‘ACE2–Ang–(1–7)–Mas axis’ plays as an angel for fruitful aging in RAS through blood pressure lowering and organ protection.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

1 de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415–472.
2 Daviet L, Lehtonen JY, Tamura K, Griese DP, Horiuchi M, Dzau VJ. Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor-interacting protein, ATIP. ATJP J Biol Chem 2007; 272: 28997–28999.
3 Dzu V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005; 23: 59–57.
4 Danser AHJ, Tom B, de Vries R, Saxena PR. L-NAME-resistant bradykinin-induced relaxation in porcine coronary artery. Circulation 2002; 105: 2523–2529.
5 Tipnis SN, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of human angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-7, but not angiotensin 2. Hypertension 1999; 34: 398–404.
6 Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of human angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-7, but not angiotensin 2. Hypertension 1999; 34: 398–404.
7 Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baroas E, Hsieh F, Acton S, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Boof W, Robinson J, Jeyaseelan R, Breitbart RE, Remuzzi G. Disruption of the Ang II type 1 receptor blocks bradykinin-induced relaxation in porcine coronary artery. Circulation 2000; 102: 2523–2532.
8 Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. FEBS Lett 1999; 451: 327–331.
9 Murphy TJ, Alexander RW, Grindling KR, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351: 233–236.
10 Robertson CM, Treatment of different subtypes of angiotensin II receptor, AT1 and AT2, with specific ACE-2 inhibitors: STAT activation by negative crosstalk. Circ Res 1999; 84: 876–882.
11 Jones ES, Vinh A, McCarthy CA, Gazsi TI, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 2008; 120: 292–316.
12 Carey RM, Padia SH. Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 2008; 19: 420–426.
13 Horiuchi M, Hayashida W, Akiyama D, Tamura K, David L, Lehtonen JY, Dzu VJ. Stimulation of different subtypes of angiotensin II receptor, AT1 and AT2, with specific ACE-2 inhibitors: STAT activation by negative crosstalk. Circ Res 1999; 84: 876–882.
14 Kuzuya Y, Tsukahara K, Horiuchi M. Angiotensin II receptor antagonist AVE0991 is an activator of the angiotensin-(1-7) A2 receptor. J Biol Chem 2001; 276: 28997–28999.
15 Kuzuya Y, Tsukahara K, Horiuchi M. Angiotensin II receptor antagonist AVE0991 is an activator of the angiotensin-(1-7) A2 receptor. J Biol Chem 2001; 276: 28997–28999.